Read by QxMD icon Read

rashed m shah

Thaker A A Alyousefi, Rashad Abdul-Ghani, Mohammed A K Mahdy, Samira M A Al-Eryani, Abdulsalam M Al-Mekhlafi, Yahia A Raja, Shamusul Azhar Shah, John C Beier
BACKGROUND: Yemen has witnessed several dengue fever outbreaks coincident with the social unrest and war in the country. The aim of the present study was to describe the knowledge, attitudes and practices (KAPs) of at-risk urban populations residing in Taiz, southwest of Yemen. In addition, factors possibly associated with poor preventive practices were investigated. METHODS: A household-based, cross-sectional survey was conducted in three urban districts encompassing 383 households...
October 7, 2016: BMC Infectious Diseases
Stephanie Mlacker, Golsa Shafa, Adam S Aldahan, Vidhi V Shah, Sahal Samarkandy, Keyvan Nouri
BACKGROUND: Zika virus (ZIKV) is an arbovirus within the Flaviviridae family, the recent spread of which has promoted public concern. METHODS: This study outlines the clinical features, potential for teratogenicity, diagnosis, and treatment of ZIKV infection. RESULTS: Zika virus is transmitted through the bite of an infected Stegomyia (= Aedes) mosquito, blood transfusion, sexual intercourse, and perinatal routes. Infection has been characterized as mildly symptomatic...
December 2016: International Journal of Dermatology
Jeffrey H Lipton, Charles Chuah, Agnès Guerci-Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Etienne, Franck E Nicolini, Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian Oehler, Stephanie Lustgarten, Victor M Rivera, Timothy Clackson, Frank G Haluska, Michele Baccarani, Jorge E Cortes, François Guilhot, Andreas Hochhaus, Timothy Hughes, Hagop M Kantarjian, Neil P Shah, Moshe Talpaz, Michael W Deininger
BACKGROUND: Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated with arterial occlusion. We investigated whether this activity and safety profile would result in superior outcomes compared with imatinib in previously untreated patients with chronic myeloid leukaemia. METHODS: The Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia (EPIC) study was a randomised, open-label, phase 3 trial designed to assess the efficacy and safety of ponatinib, compared with imatinib, in newly diagnosed patients with chronic-phase chronic myeloid leukaemia...
May 2016: Lancet Oncology
Seon Young Choi, Shah M Rashed, Nur A Hasan, Munirul Alam, Tarequl Islam, Abdus Sadique, Fatema-Tuz Johura, Mark Eppinger, Jacques Ravel, Anwar Huq, Alejandro Cravioto, Rita R Colwell
UNLABELLED: An outbreak of cholera occurred in 1991 in Mexico, where it had not been reported for more than a century and is now endemic. Vibrio cholerae O1 prototype El Tor and classical strains coexist with altered El Tor strains (1991 to 1997). Nontoxigenic (CTX(-)) V. cholerae El Tor dominated toxigenic (CTX(+)) strains (2001 to 2003), but V. cholerae CTX(+) variant El Tor was isolated during 2004 to 2008, outcompeting CTX(-) V. cholerae. Genomes of six Mexican V. cholerae O1 strains isolated during 1991 to 2008 were sequenced and compared with both contemporary and archived strains of V...
March 15, 2016: MBio
H Roger Brown, Stephen Castellino, M Reid Groseclose, Chandikumar S Elangbam, Kathryn Mellon-Kusibab, Lawrence W Yoon, Lisa D Gates, David L Krull, Neal F Cariello, Leigh Arrington-Brown, Tony Tillman, Serita Fowler, Vishal Shah, David Bailey, Richard T Miller
Nevirapine (NVP) is associated with hepatotoxicity in 1-5% of patients. In rodent studies, NVP has been shown to cause hepatic enzyme induction, centrilobular hypertrophy, and skin rash in various rat strains but not liver toxicity. In an effort to understand whether NVP is metabolized differently in a transiently inflamed liver and whether a heightened immune response alters NVP-induced hepatic responses, female brown Norway rats were dosed with either vehicle or NVP alone (75 mg/kg/day for 15 days) or galactosamine alone (single intraperitoneal [ip] injection on day 7 to mimic viral hepatitis) or a combination of NVP (75/100/150 mg/kg/day for 15 days) and galactosamine (single 750 mg/kg ip on day 7)...
January 2016: Toxicologic Pathology
Ruben Magni, Benjamin H Espina, Ketul Shah, Benjamin Lepene, Christine Mayuga, Temple A Douglas, Virginia Espina, Sally Rucker, Ross Dunlap, Emanuel F Iii Petricoin, Mary Frekko Kilavos, Donald M Poretz, Gilbert R Irwin, Samuel M Shor, Lance A Liotta, Alessandra Luchini
OBJECTIVES: Prompt antibiotic treatment of early stage Lyme borreliosis (LB) prevents progression to severe multisystem disease. There is a clinical need to improve the diagnostic specificity of early stage Lyme assays in the period prior to the mounting of a robust serology response. Using a novel analyte harvesting nanotechnology, Nanotrap particles, we evaluated urinary Borrelia Outer surface protein A (OspA) C-terminus peptide in early stage LB before and after treatment, and in patients suspected of late stage disseminated LB...
November 4, 2015: Journal of Translational Medicine
Jia Ruan, Peter Martin, Bijal Shah, Stephen J Schuster, Sonali M Smith, Richard R Furman, Paul Christos, Amelyn Rodriguez, Jakub Svoboda, Jessica Lewis, Orel Katz, Morton Coleman, John P Leonard
BACKGROUND: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy. METHODS: We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase...
November 5, 2015: New England Journal of Medicine
Daniel E Roth, Alison D Gernand, Shaun K Morris, Brendon Pezzack, M Munirul Islam, Michelle C Dimitris, Shaila S Shanta, Stanley H Zlotkin, Andrew R Willan, Tahmeed Ahmed, Prakesh S Shah, Kellie E Murphy, Rosanna Weksberg, Sanaa Choufani, Rashed Shah, Abdullah Al Mahmud
BACKGROUND: Vitamin D regulates bone mineral metabolism and skeletal development. Some observational studies have suggested that prenatal vitamin D deficiency increases the risk of adverse pregnancy and/or birth outcomes; however, there is scant evidence from controlled trials, leading the World Health Organization to advise against routine vitamin D supplementation in pregnancy. Importantly, little is known about the effect of maternal vitamin D status on infant linear growth in communities in South Asia where stunting is highly prevalent and maternal-infant vitamin D status is commonly suboptimal...
2015: Trials
Michael M Givertz, Kevin J Anstrom, Margaret M Redfield, Anita Deswal, Haissam Haddad, Javed Butler, W H Wilson Tang, Mark E Dunlap, Martin M LeWinter, Douglas L Mann, G Michael Felker, Christopher M O'Connor, Steven R Goldsmith, Elizabeth O Ofili, Mitchell T Saltzberg, Kenneth B Margulies, Thomas P Cappola, Marvin A Konstam, Marc J Semigran, Steven E McNulty, Kerry L Lee, Monica R Shah, Adrian F Hernandez
BACKGROUND: Oxidative stress may contribute to heart failure (HF) progression. Inhibiting xanthine oxidase in hyperuricemic HF patients may improve outcomes. METHODS AND RESULTS: We randomly assigned 253 patients with symptomatic HF, left ventricular ejection fraction ≤40%, and serum uric acid levels ≥9.5 mg/dL to receive allopurinol (target dose, 600 mg daily) or placebo in a double-blind, multicenter trial. The primary composite end point at 24 weeks was based on survival, worsening HF, and patient global assessment...
May 19, 2015: Circulation
David C Klinzing, Seon Young Choi, Nur A Hasan, Ronald R Matias, Enrique Tayag, Josefina Geronimo, Evan Skowronski, Shah M Rashed, Kent Kawashima, C Nicole Rosenzweig, Henry S Gibbons, Brian C Torres, Veni Liles, Alicia C Alfon, Maria Luisa Juan, Filipinas F Natividad, Thomas A Cebula, Rita R Colwell
UNLABELLED: Cholera continues to be a global threat, with high rates of morbidity and mortality. In 2011, a cholera outbreak occurred in Palawan, Philippines, affecting more than 500 people, and 20 individuals died. Vibrio cholerae O1 was confirmed as the etiological agent. Source attribution is critical in cholera outbreaks for proper management of the disease, as well as to control spread. In this study, three V. cholerae O1 isolates from a Philippines cholera outbreak were sequenced and their genomes analyzed to determine phylogenetic relatedness to V...
2015: MBio
Rahman Shah, M Rehan Khan, Tai-Hwang M Fan, Genina Ruff, Kodangudi B Ramanathan
An 81-year-old man presented with a 1-week history of dry cough. He also complained of mild dyspnea, wheezing, and low-grade fever. He denied hemoptysis, fever, rashes, or chest pain. The patient's medical history included coronary artery bypass surgery, hypertension, gastroesophageal reflux disease, and COPD. The patient was a retired welder and an ex-smoker.
February 2015: Chest
Daniela Ceccarelli, Arlene Chen, Nur A Hasan, Shah M Rashed, Anwar Huq, Rita R Colwell
Non-O1/non-O139 Vibrio cholerae inhabits estuarine and coastal waters globally, but its clinical significance has not been sufficiently investigated, despite the fact that it has been associated with septicemia and gastroenteritis. The emergence of virulent non-O1/non-O139 V. cholerae is consistent with the recognition of new pathogenic variants worldwide. Oyster, sediment, and water samples were collected during a vibrio surveillance program carried out from 2009 to 2012 in the Chesapeake Bay, Maryland. V...
March 2015: Applied and Environmental Microbiology
Catherine Lombard-Bohas, James C Yao, Timothy Hobday, Eric Van Cutsem, Edward M Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H Shah, Jaume Capdevila, Rodney Pommier
OBJECTIVE: The aim of this study was to evaluate efficacy and safety of everolimus in patients with pancreatic neuroendocrine tumors (pNET) by prior chemotherapy use in the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3). METHODS: Patients with advanced, progressive, low- or intermediate-grade pNET were prospectively stratified by prior chemotherapy use and World Health Organization performance status and were randomly assigned (1:1) to everolimus 10 mg/d (n = 207) or placebo (n = 203)...
March 2015: Pancreas
Nathan H Fowler, R Eric Davis, Seema Rawal, Loretta Nastoupil, Fredrick B Hagemeister, Peter McLaughlin, Larry W Kwak, Jorge E Romaguera, Michelle A Fanale, Luis E Fayad, Jason R Westin, Jatin Shah, Robert Z Orlowski, Michael Wang, Francesco Turturro, Yasuhiro Oki, Linda C Claret, Lei Feng, Veerabhadran Baladandayuthapani, Tariq Muzzafar, Kenneth Y Tsai, Felipe Samaniego, Sattva S Neelapu
BACKGROUND: Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as monotherapy for relapsed indolent non-Hodgkin lymphoma. We assessed the efficacy and safety of lenalidomide plus rituximab in patients with untreated, advanced stage indolent non-Hodgkin lymphoma. METHODS: In this phase 2 trial, undertaken at one instution, patients with follicular lymphoma and marginal zone lymphoma were given lenalidomide, orally, at 20 mg/day on days 1-21 of each 28-day cycle...
November 2014: Lancet Oncology
Debashis Sarker, Joo Ern Ang, Richard Baird, Rebecca Kristeleit, Krunal Shah, Victor Moreno, Paul A Clarke, Florence I Raynaud, Gallia Levy, Joseph A Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M Spoerke, Mark R Lackner, Yibing Yan, Lori S Friedman, Stan B Kaye, Mika K Derynck, Paul Workman, Johann S de Bono
PURPOSE: This first-in-human dose-escalation trial evaluated the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of pictilisib (GDC-0941), an oral, potent, and selective inhibitor of the class I phosphatidylinositol-3-kinases (PI3K). PATIENTS AND METHODS: Sixty patients with solid tumors received pictilisib at 14 dose levels from 15 to 450 mg once-daily, initially on days 1 to 21 every 28 days and later, using continuous dosing for selected dose levels...
January 1, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Ramona Dadu, Komal Shah, Naifa L Busaidy, Steven G Waguespack, Mouhammad A Habra, Anita K Ying, Mimi I Hu, Roland Bassett, Camilo Jimenez, Steven I Sherman, Maria E Cabanillas
CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation. OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. DESIGN: A retrospective review at MD Anderson Cancer Center. METHODS: The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images...
January 2015: Journal of Clinical Endocrinology and Metabolism
Nur A Hasan, Talayeh Rezayat, Peter J Blatz, Seon Young Choi, Kimberly J Griffitt, Shah M Rashed, Anwar Huq, Nicholas G Conger, Rita R Colwell, D Jay Grimes
An occurrence of Vibrio cholerae non-O1/O139 gastroenteritis in the U.S. Gulf Coast is reported here. Genomic analysis revealed that the isolate lacked known virulence factors associated with the clinical outcome of a V. cholerae infection but did contain putative genomic islands and other accessory virulence factors. Many of these factors are widespread among environmental strains of V. cholerae, suggesting that there might be additional virulence factors in non-O1/O139 V. cholerae yet to be determined. Phylogenetic analysis revealed that the isolate belonged to a phyletic lineage of environmental V...
January 2015: Journal of Clinical Microbiology
Wanida Mala, Chariya Chomvarin, Munirul Alam, Shah M Rashed, Kiatichai Faksri, Sunpetch Angkititrakul
Vibrio vulnificus can cause septicemia, wound infection and gastroenteritis. The most severe infections are related to consumption of raw or undercooked seafood. Virulence genes, biomarkers, antimicrobial resistance, and genetic relationships among V vulnificus isolated from clinical and environmental sources in Thailand have not hitherto been investigated. ViuB encoding vulnibactin siderophore was detected in 33% and 50% of clinical and environmental (cockle) V. vulnificus isolates, respectively, and capsular polysaccharide allele 1 in 67% and 75% of clinical and environmental isolates, respectively...
January 2014: Southeast Asian Journal of Tropical Medicine and Public Health
Kara Bischoff, Shilpa M Shah, Gurpreet Dhaliwal, Harry Hollander
No abstract text is available yet for this article.
September 2014: Journal of General Internal Medicine
Shah M Rashed, Andrew S Azman, Munirul Alam, Shan Li, David A Sack, J Glenn Morris, Ira Longini, Abul Kasem Siddique, Anwarul Iqbal, Anwar Huq, Rita R Colwell, R Bradley Sack, O Colin Stine
Cholera remains a major public health problem. To compare the relative contribution of strains from the environment with strains isolated from patients during outbreaks, we performed multilocus variable tandem repeat analyses on samples collected during the 2010 and 2011 outbreak seasons in 2 geographically distinct areas of Bangladesh. A total of 222 environmental and clinical isolates of V. cholerae O1 were systematically collected from Chhatak and Mathbaria. In Chhatak, 75 of 79 isolates were from the same clonal complex, in which extensive differentiation was found in a temporally consistent pattern of successive mutations at single loci...
January 2014: Emerging Infectious Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"